In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Hoya, Eclipse in aesthetic laser pact:

This article was originally published in Clinica

Executive Summary

Dental and aesthetic medical laser specialist Hoya ConBio has signed an exclusive three-year distribution agreement with Eclipse Medical for its MedLite C series and RevLite lasers. Eclipse will distribute the lasers in Texas, Louisiana, Arkansas and Oklahoma. Hoya (Freemont, California) claims that the MedLite C series and RevLite lasers, which use Q-switched Nd:YAG laser engineering, represent the next generation of laser engineering. This is because they treat patients via the delivery of energy with a "PhotoAcoustic" effect, as opposed to photothermal energy, which other devices use. These lasers are already used widely for tattoo removal, but also have potential uses for wrinkle reduction, acne scars, vascular and pigmented lesions and hair removal.

You may also be interested in...

Pandemic Response In US Consumer Health Market: OTC Pain Relief And Cough/Cold Purchases

Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.

venBio Raises $394m To Fund Biopharmas Through Human Proof-Of-Concept

Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.

FDA Wants To Put Hep C Tests On 510(k) Pathway

The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts